How to Invest in CRISPR Therapeutics Stock

By Lyle Daly – Updated Sep 17, 2025 at 11:07 AM | Fact-checked by Margo Winton Parodi

Key Points

Casgevy, CRISPR Therapeutics's first approved treatment, targets sickle cell disease and beta-thalassemia.
CRISPR is developing additional therapies for cancer and cardiovascular diseases using gene editing.
Investors should prepare for long-term holding and high volatility due to CRISPR's early-stage products.

CRISPR Therapeutics (CRSP +6.75%) could revolutionize the healthcare sector, and that has made CRISPR stock a hot buy. While the company isn't profitable yet, it had its first treatment (for sickle cell disease) approved by regulators in December 2023.

It also has promising treatments in the works for cancer and cardiovascular disease, all utilizing the CRISPR gene editing platform. If you're thinking about investing in CRISPR stock, here's how to do it and what you should know first.

Loading paragraph...

NASDAQ: CRSP

CRISPR Therapeutics

Today's Change

(6.75%) $3.45

Current Price

$54.56

Key Data Points

Market Cap

$5B

Day's Range

$49.11 - $54.64

52wk Range

$30.04 - $78.48

Volume

2.7M

Avg Vol

2.4M

Gross Margin

-36522.94%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

Loading pitch...

Stock Ticker

A shorthand code of letters representing a company's stock for trading purposes, displayed on financial platforms.

Loading definition...

Loading paragraph...

Buy-and-Hold Strategy

A strategy that entails buying stocks or other securities and not selling them for long periods of time, sometimes decades.

Loading definition...

Loading paragraph...

Loading pitch...

Loading paragraph...

Related investing topics

Loading paragraph...

Biotech vs. Pharma: What's the Difference?

While there is a lot of overlap between biotech and pharma, there are some key differences.

Investing in Pharmaceutical Stocks

The makers of the medicines that keep us happy and healthy can be great places to invest.

Investing in Biotech Stocks in 2025

These companies create drugs and treatments for some of the biggest medical problems of our time.

Investing in Genomics Stocks

Learn how to invest in the growing industry of genomics and get a list of the field's most promising companies.

Loading hub_pages...

Loading paragraph...

Loading pitch...

Loading paragraph...

Loading faq...

About the Author

Lyle Daly is a contributing Motley Fool stock market analyst covering information technology and cryptocurrency. Lyle has been a contributor at the financial services company since 2018. His work has been featured on USA Today, Yahoo Finance, MSN, Fox Business, and Nasdaq. Before joining The Motley Fool, he wrote for financial brands including Intuit.

TMFLyleDaly

@LyleDaly

Lyle Daly has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.